Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma
| Autor: | Neofit Spasov, Mariya I. Spasova |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Dinutuximab Induction chemotherapy Case Report General Medicine Disease Multimodality Therapy medicine.disease Pediatrics Pediatric cancer RJ1-570 03 medical and health sciences 0302 clinical medicine Maintenance therapy 030220 oncology & carcinogenesis Internal medicine Neuroblastoma medicine 030212 general & internal medicine business |
| Zdroj: | Case Reports in Pediatrics Case Reports in Pediatrics, Vol 2021 (2021) |
| ISSN: | 2090-6811 2090-6803 |
| Popis: | Neuroblastoma is the most common extracranial solid tumor in children, accounting for 15% of all pediatric cancer deaths. High-risk neuroblastoma (HRNB) is a particularly difficult-to-treat form of the disease that requires aggressive multimodality therapy, including induction chemotherapy, consolidation therapy with high-dose chemotherapy and autologous stem cell transplant, and maintenance therapy with dinutuximab beta. Despite treatment advances, the prognosis of these patients remains poor. As a better response to induction therapy has been associated with prolonged survival in patients with HRNB, we hypothesized that early use of dinutuximab beta—post-induction chemotherapy—may improve patient outcomes. We describe here our experience of administering at least one cycle of dinutuximab beta post-induction and prior to surgery in three children with HRNB who did not demonstrate a complete response to induction chemotherapy. All three patients achieved complete remission. Early use of dinutuximab beta may therefore have the potential to improve outcomes in patients with HRNB. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|